Mumbai, November 18, 2024: Global pharma major Lupin Limited (Lupin) announced the re-launch of Humrahi at the Research Society for the Study of Diabetes in India (RSSDI) conference in New Delhi. Humrahi is now enhanced with comprehensive support for both diabetes and heart health.

With diabetes and cardiovascular diseases ranking among the top health challenges globally, Humrahi represents a critical innovation that combines extensive support for diabetes management along with robust care strategies for heart health. This dual focus aims to offer patients a holistic approach to health management.

This launch builds on the proven success of Humrahi, which has been instrumental in guiding patients toward better diabetes management. The enhanced version now includes cardiovascular care, providing patients with insights into heart-healthy practices, regular monitoring, and expert guidance on managing cardiovascular risks associated with diabetes.

“Humrahi is a unique initiative designed to improve patient outcomes by addressing one of healthcare’s biggest challenges – non-adherence to therapy. It actively supports patients in managing their conditions through value-based support and care, raises awareness, bridging gaps that often prevent adherence and, ultimately, improves health outcomes,” said Rajeev Sibal, President India Region Formulations, Lupin.

Kapil Dev, cricketing legend and Humrahi’s brand ambassador, stated, “Trusting Humrahi is like trusting your best teammate. It’s a reliable platform that provides consistent support for managing chronic conditions.”

Dr. B M Makkar, Organizing Chairman, RSSDI said, “Humrahi stands out as it empowers patients to take charge of their own health journey with ease.”

Dr. Banshi Saboo, Chair-Elect, International Diabetes Federation for Southeast Asia commented, “The program focuses on NCD through a customized unique approach highlighting the importance of education and awareness in the patient journey. It is a complete solution that we have long needed in healthcare.”

Dr. Anuj Maheshwari, President Elect, RSSDI noted, “Humrahi’s unique approach to ensuring patient privacy and offering tailored support and guidance makes it one of the most patient-friendly platforms experienced by us.”

Patients can access Humrahi through the Play Store, App Store, or https://humrahi.co.in. Additionally, they can receive personalized support by connecting with a dedicated care executive at the toll-free number 7808777777.

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact –

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com